These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19936342)

  • 1. Treatment monitoring with 18F-FDG PET in metastatic thymoma after 90Y-Dotatoc and selective internal radiation treatment (SIRT).
    Vasamiliette J; Hohenberger P; Schoenberg S; Diehl S; Dinter DJ; Marx A; Stroebel P; Strauss LG; Dimitrakopoulou-Strauss A
    Hell J Nucl Med; 2009; 12(3):271-3. PubMed ID: 19936342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
    Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P
    Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
    Gulec SA; Pennington K; Wheeler J; Barot TC; Suthar RR; Hall M; Schwartzentruber D
    Am J Clin Oncol; 2013 Oct; 36(5):455-60. PubMed ID: 22643569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment response in liver metastases following 90Y SIR-spheres: an evaluation with PET.
    Lin M; Shon IH; Wilson R; D'Amours SK; Schlaphoff G; Lin P
    Hepatogastroenterology; 2007; 54(75):910-2. PubMed ID: 17591090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
    Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease.
    Turkmen C; Ucar A; Poyanli A; Vatankulu B; Ozkan G; Basaran M; Serin K; Sanli Y; Adalet I
    Cancer Biother Radiopharm; 2013 Sep; 28(7):534-40. PubMed ID: 23647219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases.
    Dierckx R; Maes A; Peeters M; Van De Wiele C
    Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):336-42. PubMed ID: 19521313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordant F-18 FDG PET and Y-90 Bremsstrahlung scans depict selective delivery of Y-90-microspheres to liver tumors: confirmation with histopathology.
    Tehranipour N; AL-Nahhas A; Canelo R; Stamp G; Woo K; Tait P; Gishen P
    Clin Nucl Med; 2007 May; 32(5):371-4. PubMed ID: 17452865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.
    Wong CY; Qing F; Savin M; Campbell J; Gates VL; Sherpa KM; Lewandowski RJ; Nagle C; Salem R
    J Vasc Interv Radiol; 2005 Aug; 16(8):1101-6. PubMed ID: 16105922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data.
    Middendorp M; Selkinski I; Happel C; Kranert WT; Grünwald F
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):76-83. PubMed ID: 20168289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases.
    Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Amesur N; Avril N
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):723. PubMed ID: 15599525
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of 18F-FDG-PET and PET/CT in patients with colorectal liver metastases undergoing selective internal radiation therapy with yttrium-90: a first evidence-based review.
    Annunziata S; Treglia G; Caldarella C; Galiandro F
    ScientificWorldJournal; 2014; 2014():879469. PubMed ID: 24672385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of flourine-18 fluorodeoxyglucose positron emission tomography in thymic pathology.
    El-Bawab H; Al-Sugair AA; Rafay M; Hajjar W; Mahdy M; Al-Kattan K
    Eur J Cardiothorac Surg; 2007 Apr; 31(4):731-6. PubMed ID: 17293120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
    Lewandowski RJ; Thurston KG; Goin JE; Wong CY; Gates VL; Van Buskirk M; Geschwind JF; Salem R
    J Vasc Interv Radiol; 2005 Dec; 16(12):1641-51. PubMed ID: 16371530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
    Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
    Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study.
    Ruers TJ; Wiering B; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Krabbe PF; Oyen WJ
    J Nucl Med; 2009 Jul; 50(7):1036-41. PubMed ID: 19525451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET?
    Tochetto SM; Rezai P; Rezvani M; Nikolaidis P; Berggruen S; Atassi B; Salem R; Yaghmai V
    Radiology; 2010 Apr; 255(1):164-72. PubMed ID: 20308454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET.
    Wong CY; Salem R; Qing F; Wong KT; Barker D; Gates V; Lewandowski R; Hill EA; Dworkin HJ; Nagle C
    J Nucl Med; 2004 Nov; 45(11):1892-7. PubMed ID: 15534060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.